Spyre Therapeutics, Inc. SYRE Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s business segments — stock-based comp?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — stock-based comp of $12.81M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — stock-based comp changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — stock-based comp increased by 44.6% year-over-year, from $8.86M to $12.81M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — stock-based comp?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — stock-based comp has grown at a 74.2% compound annual growth rate (CAGR), from $7.11M to $37.61M.
- What does business segments — stock-based comp mean?
- The non-cash cost of equity awards granted to employees in this segment.
- How do you interpret business segments — stock-based comp?
- Higher levels indicate aggressive talent acquisition or retention strategies, though they dilute existing shareholders.
- How does business segments — stock-based comp compare across companies?
- Common in high-growth biotech companies; investors compare this to total compensation to assess the equity-to-cash mix.